Addex Therapeutics Ltd
0QNV.L
London Stock Exchange0.04
CHF
+0.00
- -
Addex Therapeutics Ltd
0QNV.L
(London Stock Exchange)
Recent
price
0.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Addex Therapeutics Ltd (SIX: ADXN) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes small-molecule allosteric modulators targeting neurological disorders. The company offers a pipeline of orally available therapeutics, including dipraglurant (mGlu5 NAM) in Phase 2 for Parkinson's disease levodopa-induced dyskinesia (PD-LID), Phase 1 for post-stroke and traumatic brain injury sensorimotor recovery, and preparation for registration trials in PD-LID; ADX71149 (mGlu2 PAM), previously partnered with Janssen Pharmaceuticals for schizophrenia and anxious depression and now under internal evaluation; GABAB PAM programs through collaboration with Indivior for substance use disorders, with IND-enabling studies completed, and independently for chronic cough, overactive bladder, pain and other disorders; and preclinical candidates such as mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. Addex Therapeutics holds a 20% equity stake in Neurosterix LLC, a spin-out advancing allosteric modulators including M4 PAM for schizophrenia. Founded in 2002 and headquartered in Geneva, Switzerland, the company operates primarily in Europe with subsidiaries in Switzerland, France and the United States, and focuses on G-protein coupled receptors and enzymes for the biotechnology sector. Recent developments include Indivior's selection and IND-enabling completion of a GABAB PAM for substance use disorders in 2025; advancement of independent GABAB PAM for chronic cough toward IND-enabling studies subject to financing; Q1 2025 financial results showing reduced income but ongoing pipeline execution; and a CHF 2 million investment in Stalicla SA to support strategic growth.